Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD30 in normal and neoplastic cells.

R Chiarle1, A Podda, G Prolla

  • 1Department of Pathology and Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, New York 10016, USA.

Clinical Immunology (Orlando, Fla.)
|March 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of class III peroxidase pathways and phenylpropanoids in Arundo donax under salt and phosphorus stress.

Plant physiology and biochemistry : PPB·2022
Same author

Local Polarization and Isothermal Local Equilibrium in Relativistic Heavy Ion Collisions.

Physical review letters·2022
Same author

Posterior interosseous nerve of the elbow at the arcade of Frohse: Ultrasound appearance in asymptomatic subjects.

Diagnostic and interventional imaging·2019
Same author

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Blood cancer journal·2018
Same author

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Leukemia·2016
Same author

Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Leukemia·2016

CD30, a molecule identified in 1982, plays a key role in diagnosing Hodgkin's Disease and Anaplastic Large Cell Lymphoma. Its function in lymphoid development and differentiation is increasingly understood.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • CD30 (Ki-1) molecule identified in 1982.
  • Expressed by Reed-Sternberg cells in Hodgkin's Disease (HD).
  • Crucial for differential diagnosis of HD and identifying Anaplastic Large Cell Lymphoma (ALCL).

Purpose of the Study:

  • Provide an overview of CD30 research.
  • Discuss the role of CD30 in normal lymphoid cells.
  • Discuss the role of CD30 in neoplastic lymphoid cells.

Main Methods:

  • Cloning of human and murine CD30.
  • Utilizing genetically manipulated animal models.

Main Results:

  • Expanded knowledge on CD30's physiological role.

Related Experiment Videos

  • Characterization of CD30's function in lymphoid development and differentiation.

    • Conclusions:

    • CD30 is vital in diagnosing lymphoid malignancies.
    • CD30 influences normal lymphoid cell development.
    • CD30 is implicated in neoplastic lymphoid cell behavior.